Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FSHR | P23945 | 14/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | REV1 | Q9UBZ9 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1323708 | 0.90 | FSHR (0.67) | FSHRSMN1; SMN2TSHRMEN1KMT2A | |
| SCHEMBL1322172 | 0.84 | FSHR (0.77) | FSHRTSHRMEN1KMT2AADRB2 | |
| SCHEMBL1323458 | 0.83 | FSHR (0.76) | FSHRTSHRMEN1KMT2AADRB2 | |
| SCHEMBL1322220 | 0.81 | FSHR (0.73) | FSHRTSHRMEN1KMT2AADRB2 | |
| SCHEMBL1323766 | 0.81 | FSHR (0.71) | FSHRTSHRMEN1KMT2AADRB2 | |
| SCHEMBL2189817 | 0.80 | FSHR (0.70) | FSHRTSHRMEN1KMT2AADRB2 | |
| SCHEMBL1322898 | 0.80 | FSHR (1.00) | FSHRTSHRMEN1KMT2AADRB2 | |
| SCHEMBL1323666 | 0.79 | FSHR (0.88) | FSHRTSHRMEN1KMT2AADRB2 | |
| SCHEMBL1322243 | 0.77 | FSHR (0.76) | FSHRTSHRMEN1KMT2AADRB2 | |
| SCHEMBL1323493 | 0.77 | FSHR (0.76) | FSHRTSHRMEN1KMT2AADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8258293-B2 | Tetrahydroquinoline derivatives | MSD OSS B.V. (NL) | 2012-09-04 | — | — | US | disclosed |
| US-20120202996-A1 | TETRAHYDROQUINOLINE DERIVATIVES | N.V. ORGANON (NL) | 2012-08-09 | — | — | US | disclosed |
| US-8058441-B2 | For control fertility, contraception, breast cancer, prostate cancer and endometriosis; modulating activity of the follicle stimulating hormone (FSH) receptor; 1-Acetyl-6-(tert-butoxycarbonyl)amino-4-phenyl-1,2,3,4-tetrahydro-2,2,4-trimethylquinoline | N.V. ORGANON (NL) | 2011-11-15 | — | — | US | disclosed |
| EP-1406628-B1 | TETRAHYDROQUINOLINE DERIVATIVES | AKZO NOBEL NV (NL) | 2006-03-08 | — | — | EP | disclosed |
| US-20040236109-A1 | Tetrahydroquinoline derivatives | MERCK SHARP & DOHME B.V. (NL) | 2004-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202996-A1 | TETRAHYDROQUINOLINE DERIVATIVES | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, ODC1, COX6C | FSHR 1154/4885SMN1; SMN2 1780/4885TSHR 412/4885 |
| US-20040236109-A1 | Tetrahydroquinoline derivatives | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, AOC2, HTR3C | FSHR 1485/4885SMN1; SMN2 1582/4885TSHR 725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.